Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
After ice and snow, a more dry and settled picture across the UK today - but it's still set to be chilly.
Drunks who become abusive in hospital A&Es should be arrested, a leading doctor has claimed.
This was despite more than a fifth experiencing delays of more than three hours, a Which? survey revealed.